MedTrace Logo

A Study of LY03015 in Healthy Chinese and Caucasian Adult Subjects

NCT07671833 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-06-26

No results posted yet for this study

Summary

This is an open-label, single-dose, parallel-group study to evaluate the safety, tolerability and pharmacokinetic characteristics of LY03015 in healthy Chinese and Caucasian adult subjects. The duration of study will be around up to 42 days for each participant, including up to 14 days of screening period, baseline visit, and a 28-day safety assessment period with a 7-day/6-night stay in the clinical research unit.

Conditions

  • Healthy Participants

Interventions

DRUG

LY03015 (LPM3770164 extended-release tablets)

LY03015 (LPM3770164) is an investigational extended-release tablet administered. LY03015, a new generation dual-target drug is a selective VMAT2 inhibitor and sigma-1 receptor.

Sponsors & Collaborators

  • Luye Pharma Group Ltd.

    lead INDUSTRY

Principal Investigators

  • Jiebo Lu · Luye Pharma (USA), Ltd.

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-04-15
Primary Completion
2026-05-08
Completion
2026-05-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07671833 on ClinicalTrials.gov